According to American Cancer Society estimates, the incidence of synovial sarcoma in the U.S. for
2018 is expected to be 13,040 patients out of which 7,370 in males and 5,670 in females. Extensive
research & development in this field for the development of innovative therapies for the treatment
of synovial sarcoma is expected to boost the global synovial sarcoma treatment market growth over
the forecast period. For instance, organizations such as Accuronix Therapeutics, Advenchen
Laboratories, LLC, Immune Design, Cue Biopharma, and others are working on research and
development of novel immunotherapy candidates for the treatment of synovial sarcoma. Accuronix
Therapeutics has ACXT-3102, a small molecule drug conjugate, in preclinical development for
treatment of synovial sarcoma and other cancers. Advanchen Laboratories has AL3818 (anlotinib)
in Phase 3 clinical trials for the treatment of synovial sarcoma (SS), and other indications.
Moreover, Immune Design has an antigen-specific prime boost CMB305 in Phase 2 clinical trials
for synovial sarcoma. Cue Biopharma is working on CUE-102, a potential treatment for melanoma,
synovial sarcoma, prostate, and head and neck cancers.
Adaptimmune Therapeutics received T-Cell therapy breakthrough designation by the U.S. Food &
Drug Administration (FDA) for its NY-ESO-1 T-cell therapy in 2016. Immunocore, a U.K. based
biotechnology company is working on ImmTAC (Immune mobilizing monoclonal TCRs), which
has potential applications in various cancers including synovial sarcoma. Furthermore, research on
novel vaccines for the treatment of synovial sarcoma is also underway, which could increase the
treatment options for synovial sarcoma. These factors are expected to boost growth of the synovial
sarcoma treatment market over the forecast period.
However, the side effects associated with cancer treatment, high costs, and uncertainty of the results
of clinical trials is expected to affect the growth of the market over the forecast period.
Synovial Sarcoma Treatment Market Regional Insights
North America is expected to witness significant growth over the forecast period due to research
and development, and high prevalence of the synovial sarcoma. Immunotherapy is a popular
treatment in the region, wherein, application of immunotherapies such as checkpoint-inhibitors and
adoptive T cell therapy is being researched for the treatment of synovial sarcoma. Another approach
that is being studied, is the combination therapy including two or more immunotherapy candidates,
which have shown potential effects in the synovial sarcoma treatment. For instance, positive results
of phase 2 studies of the combination of Axitinib and Pembrolizumab in the treatment of advanced
alveolar soft part sarcoma and other soft tissue sarcomas were presented at Connective Tissue
Oncology Society Annual Meeting in 2017. Moreover, Europe region is expected to witness high
growth, owing to presence of innovative biotech companies such as Immunocore, which are
actively involved in research and development of targeted therapies such as ImmTAC.
For More Information @ https://www.coherentmarketinsights.com/ongoing-insight/synovial-
sarcoma-treatment-market-1571
Key players operating in Synovial Sarcoma Treatment Market include Pfizer, Inc., Eli Lilly and
Company, Genentech USA, F. Hoffmann-La Roche Ltd, Johnson & Johnson, GlaxoSmithKline,
Bristol-Myers Squibb, Teva Pharmaceuticals, and Celgene Corporation among others.
Synovial Sarcoma Treatment Market Taxonomy-
The global synovial sarcoma treatment market is segmented on the basis of treatment type, end user,
and geography.
By Treatment Type-
•Chemotherapy